Fibroblast Growth Factor-23 as a prognostic and diagnostic biomarker for feline chronic kidney disease
Lead Research Organisation:
Royal Veterinary College
Department Name: Comparative Biomedical Sciences CBS
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Organisations
People |
ORCID iD |
| Jonathan Elliott (Principal Investigator) |
Publications
Sargent HJ
(2019)
Fibroblast growth factor 23 and symmetric dimethylarginine concentrations in geriatric cats.
in Journal of veterinary internal medicine
| Description | Market research report to assess likely demand for a test, based on a specific marker - "FGF-23", to help assess risk in cats of developing chronic kidney disease, and response to dietary interventions. "Freedom to operate" report to identify the owners of intellectual property (patent) rights, that would govern the commercialisation of such a test. |
| Exploitation Route | Findings indicate that there is market potential for a diagnostic company to develop a product, subject to obtaining licence rights from patent owners. |
| Sectors | Pharmaceuticals and Medical Biotechnology,Other |
| Description | Does phosphate restriction normalise elevated circulating FGF-23 concentrations in early CKD in cats? |
| Amount | £236,000 (GBP) |
| Organisation | Royal Canin |
| Sector | Private |
| Country | France |
| Start | 11/2016 |
| End | 10/2020 |
| Title | FGF23 as a diagnostic and monitoring tool in Veterinary Clinical Diagnostics |
| Description | Based on our published work and advocacy, IDEXX have licensed serum FGF23 for veterinary use and are marketing this test for managing and monitoring phosphorous overload in chronic kidney disease. (see https://www.idexx.co.uk/en-gb/veterinary/reference-laboratories/fgf-23/) . This test is now available to vets in clinical practice who diagnose chronic kidney disease (CKD) early in cats through health screening and want to know whether dietary phosphate restriction is warranted. We have advocated this approach principally because not all cats with CKD respond well to the clinical diets that are on the market for managing CKD at this early stage. FGF23 is elevated in those cats that go on to develop more severe CKD and we have demonstrated that introducing diets to cats with more severe CKD is beneficial to their survival. IDEXX cite one of our papers highlighting the predictive value of FGF23 and a recent review article where we outline why dietary phosphate (particularly in the inorganic form) is damaging to cat kidneys. Our work on CKD Bone Mineral Disorder is primarily funded by Royal Canin Ltd., part of the MARS groups of companies. We are conducting clinical trials with them to determine the benefit of clinical renal diets in early stage CKD and to assess the benefit of magnesium supplementation on cats with CKD. This area of research and development featured as one of the RVC's Impact case studies in REF2021 (see https://results2021.ref.ac.uk/impact/5afadee4-ec54-4cc7-97db-07af6907df45?page=1 ). The text redacted for publication under sources corroborating the impact (source a. from IDEXX) outlined their intention to market FGF23 as a diagnostic test. |
| Type | Diagnostic Tool - Non-Imaging |
| Current Stage Of Development | Wide-scale adoption |
| Year Development Stage Completed | 2022 |
| Development Status | Under active development/distribution |
| Impact | The International Renal Interest Society has incorporated FGF23 into its treatment and monitoring guidelines (accepted standard of care) for cats with chronic kidney disease. See http://www.iris-kidney.com/pdf/IRIS_CAT_Treatment_Recommendations_2023.pdf |
| URL | https://www.idexx.co.uk/en-gb/veterinary/reference-laboratories/fgf-23/ |
| Description | 4 Lectures to veterinary practitioners in St Petersburg, Russia as part of a conference |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Spoke at a conference in St-Petersburg, giving 4 hours of lectures on Feline Chronic Kidney Disease. The conference was organised by the Association of Veterinary Clinic of Saint-Petersburg. Most significant outcome was the translation of this new knowledge to veterinary practitioners in Russia. |
| Year(s) Of Engagement Activity | 2017 |
| Description | Talk to clinicians at the Huazhong Agricultural University Veterinary Hospital |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Presentation to clinicians at Huazhong Agricultural University Veterinary Hospital, China. The title of the talk was Bone and Mineral Disturbances in cats with CKD. Most significant outcome was the translation of this new knowledge to veterinary practitioners in China. |
| Year(s) Of Engagement Activity | 2017 |